Engineered Extracellular Vesicles (EVs) as Carriers for CRISPR/Cas9 Therapeutics: Recent Advances in Cargo Loading and Targeted Delivery.
The therapeutic potential of CRISPR/Cas genome editing has advanced the development of precision medicine; however, its clinical translation for many in vivo applications remains limited by challenges in achieving safe, efficient, and targeted delivery. Conventional viral vectors and synthetic nanocarriers are associat...